Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use among Patients with Fibromyalgia Newly Prescribed Gabapentin or Pregabalin
dc.contributor.author | Gore, Mugdha | en_US |
dc.contributor.author | Sadosky, Alesia Beth | en_US |
dc.contributor.author | Zlateva, Gergana | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.date.accessioned | 2010-06-01T20:37:52Z | |
dc.date.available | 2010-06-01T20:37:52Z | |
dc.date.issued | 2009-09 | en_US |
dc.identifier.citation | Gore, Mugdha; Sadosky, Alesia Beth; Zlateva, Gergana; Clauw, Daniel J. (2009). "Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use among Patients with Fibromyalgia Newly Prescribed Gabapentin or Pregabalin." Pain Practice 9(5): 363-374. <http://hdl.handle.net/2027.42/73737> | en_US |
dc.identifier.issn | 1530-7085 | en_US |
dc.identifier.issn | 1533-2500 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73737 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19500273&dopt=citation | en_US |
dc.description.abstract | Objective: To characterize comorbidities, pain-related pharmacotherapy, and healthcare resource use among patients with fibromyalgia (FM) newly prescribed pregabalin or gabapentin in clinical practice. Methods and design: Using the PharMetrics ® Database, FM patients (International Classification of Diseases, Ninth Revision, Clinical Modification code 729.1X) newly prescribed pregabalin ( n = 1,606; mean age 49.9 ± 9.6 years; 87.9% female) and gabapentin ( n = 930; mean age 49.5 ± 9.6 years; 86.6% female) on/after July 1, 2007 were identified. Prevalence of comorbidities, pharmacotherapy, and healthcare resource use/costs (pharmacy, outpatient, inpatient, total) were examined during the 6 months preceding (preindex) and following (postindex) the date of their first pregabalin or gabapentin (index) prescription. Results: Patients in both cohorts had a variety of comorbidities and used multiple medications. There were significant decreases ( P values < 0.05) in the use of nonsteroidal anti-inflammatory drugs (32.1% vs. 29.5%), anticonvulsants (27.0% vs. 22.0%), and combination therapies in the pregabalin cohort in the postindex period. There were significant increases (all P values < 0.05) in use of short-acting opioids (58.8% vs. 63.7%), any opioids (61.5% vs. 65.6%), serotonin–norepinephrine reuptake inhibitors (22.5% vs. 24.5%), anticonvulsants (16.3% vs. 26.2%), benzodiazepines (33.2% vs. 36.6%), topical agents (6.6% vs. 9.0%), and combination therapies in the gabapentin cohort. Although there were no changes in units of healthcare resources used, there were increases in the postindex period in hospitalization, medications, and total costs for pregabalin, and office visits and medication costs for gabapentin (all P values < 0.05). Conclusions: Results suggest a high comorbidity and medication use burden in FM patients in this study. Further evaluation is warranted to clarify differences in resource utilization/costs observed with these two anticonvulsants. | en_US |
dc.format.extent | 113977 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | Journal compilation © 2009 World Institute of Pain | en_US |
dc.subject.other | Fibromyalgia | en_US |
dc.subject.other | Comorbidity | en_US |
dc.subject.other | Disease Burden | en_US |
dc.subject.other | Treatment Patterns | en_US |
dc.subject.other | Pregabalin | en_US |
dc.subject.other | Gabapentin | en_US |
dc.title | Clinical Characteristics, Pharmacotherapy and Healthcare Resource Use among Patients with Fibromyalgia Newly Prescribed Gabapentin or Pregabalin | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Anesthesiology and Medicine, University of Michigan, Ann Arbor, Michigan, U.S.A. | en_US |
dc.contributor.affiliationother | * Avalon Health Solutions, Inc., Philadelphia, Pennsylvania; | en_US |
dc.contributor.affiliationother | Pfizer, Inc.—Global Outcomes Research, New York, New York; | en_US |
dc.identifier.pmid | 19500273 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73737/1/j.1533-2500.2009.00292.x.pdf | |
dc.identifier.doi | 10.1111/j.1533-2500.2009.00292.x | en_US |
dc.identifier.source | Pain Practice | en_US |
dc.identifier.citedreference | Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38: 19 – 28. | en_US |
dc.identifier.citedreference | Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990; 33: 160 – 172. | en_US |
dc.identifier.citedreference | Wolfe F. The epidemiology of fibromyalgia. J Musculoskeletal. Pain. 1993; 1: 137 – 148. | en_US |
dc.identifier.citedreference | Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008; 73: 114 – 120. | en_US |
dc.identifier.citedreference | White L, Birnbaum H, Kaltenboeck A, Samuels S, Mallett D, Robinson R. Medical care and APS guideline-related prescription drug use in newly diagnosed and established fibromyalgia patients [ Abstract ]. J Pain. 2008; 9: 16. | en_US |
dc.identifier.citedreference | Hughes G, Martinez C, Myon E, Taieb C, Wessely S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum. 2006; 54: 177 – 183. | en_US |
dc.identifier.citedreference | Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008; 58: 895 – 902. | en_US |
dc.identifier.citedreference | Bennett RM, Jones J, Turk DC, Matallana L. An Internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007; 8: 27. | en_US |
dc.identifier.citedreference | Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007; 61: 1498 – 1508. | en_US |
dc.identifier.citedreference | White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. The London Fibromyalgia Epidemiology Study. Arthritis Rheum. 1999; 42: 76 – 83. | en_US |
dc.identifier.citedreference | White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008; 50: 13 – 24. | en_US |
dc.identifier.citedreference | Berger A, Martin S, Dukes E, Edelsberg J, Oster G. Patterns of pain-related pharmacotherapy in patients with fibromyalgia. Manag Care Interface. 2008; 20: 30 – 38. | en_US |
dc.identifier.citedreference | Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin. 2008; 24: 2489 – 2499. | en_US |
dc.identifier.citedreference | Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clinic Proc. 1999; 74: 385 – 398. | en_US |
dc.identifier.citedreference | Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002; 4: 299 – 305. | en_US |
dc.identifier.citedreference | Burckhardt C, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005. | en_US |
dc.identifier.citedreference | Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008; 67: 536 – 541. | en_US |
dc.identifier.citedreference | 18. Lyrica (Pregabalin) Capsules Prescribing Information. June. New York: Pfizer, Inc.; 2007. | en_US |
dc.identifier.citedreference | 19. Cymbalta (Duloxetine Hydrochloride) Delayed Release Capsules Prescribing Information. August. Indianapolis, IN: Eli Lilly and Company; 2008. | en_US |
dc.identifier.citedreference | 20. Savella (Milnacipran Hydrochloride) Prescribing Information. January. St. Louis, MO: Forest Pharmaceuticals; 2009. | en_US |
dc.identifier.citedreference | Arnold LM, Goldenberg D, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007; 56: 1336 – 1344. | en_US |
dc.identifier.citedreference | Dworkin RH, O'Connor PW, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007; 132: 237 – 251. | en_US |
dc.identifier.citedreference | Wesche D, Bockbrader H. A pharmacokinetic comparison of pregabalin and gabapentin [ Abstract ]. J Pain. 2005; 6 ( suppl 3 ): S29. | en_US |
dc.identifier.citedreference | Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008; 4: 605 – 614. | en_US |
dc.identifier.citedreference | Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin. J Pain. 2000; 2 ( suppl 16 ): S101 – 105. | en_US |
dc.identifier.citedreference | Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004; 5: 143 – 149. | en_US |
dc.identifier.citedreference | Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60: | en_US |
dc.identifier.citedreference | Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004; 63: 959 – 965. | en_US |
dc.identifier.citedreference | Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc. 2006; 81: S12 – S25. | en_US |
dc.identifier.citedreference | Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006; 13: 1153 – 1169. | en_US |
dc.identifier.citedreference | Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007; 12: 13 – 21. | en_US |
dc.identifier.citedreference | Finnerup N, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005; 118: 289 – 305. | en_US |
dc.identifier.citedreference | 33. World Health Organization. Cancer Pain Relief. Geneva, Switzerland: Health Organization; 1996. | en_US |
dc.identifier.citedreference | Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52: 1264 – 1273. | en_US |
dc.identifier.citedreference | Arnold L, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005; 119: 5 – 15. | en_US |
dc.identifier.citedreference | Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997; 40: 1560 – 1570. | en_US |
dc.identifier.citedreference | 37. Neurontin (Gabapentin) Prescribing Information. January. New York: Pfizer, Inc.; 2007. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.